TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: convexity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee joint laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean morphine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day mortality risk
Endpoint domain: Mortality/survival
Primary endpoint: Height SD score gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-determination scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: internet addiction scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Restless Legs Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Johns Hopkins Restless Legs Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of withdrawal bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: duodenal ulcer relapse rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: toxicity during chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Improvements in Yeaple, air blast and VAS responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total VA intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean serum retinol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of tolerance to CM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheal size in SPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milk-specific IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agitated behavior symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported subjective distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: post-task appraisals of the TSST as threatening and challenging
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: negative mood ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean monthly income
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: maintenance of employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patients' self-reported social functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: mean misoprostol requirement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Grade III/IV anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Widespread pressure pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AST levels after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Log colony-forming units (CFU) on palms and fingers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in VLDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of major cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: %SHR of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔΔZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hypoxemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prostate-specific antigen doubling time (PSADT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: two-point thresholds on the upper lip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: warmth detection thresholds on the lower vermilion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cool detection thresholds on the lower vermilion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Likelihood to repeat successful soothing technique
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frustration when soothing failed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: GLP-1 release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GLP-2 release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in PHQ9 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time for sensory block to reach T4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-year recall rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization due to CHF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blood flow velocity in the central retinal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: retinal capillary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pelvic incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: patient self-evaluation score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intra-abdominal adipose tissue mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: non‐CABG major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: subacute ST
Endpoint domain: Adverse events/effects
Primary endpoint: net adverse clinical events (NACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean LVEF improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in episodes of nonsustained ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of cardiovascular morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: total percentage of body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting plasma bicarbonate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total work completed in intermittent sprints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dextromethorphan urinary metabolic ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fracture strength values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular training intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Timely TMT-B completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for TMT-B completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Error-free TMT-A performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-attempt insertion success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Oropharyngeal seal pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: active GLP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average AdSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dilatation of the proximal stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cue-elicited craving for tobacco
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Grade I (mild) reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient activation as measured by the UK PAM‐13
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Low sexual desire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Low sexual satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Bioavailability of dutasteride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak exposure to dutasteride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life in emotional functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: quality of life in activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: quality-adjusted survival time
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage change in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: sealant retention rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caries prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value for pulmonary embolism (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KCCQ-OS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of completed procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: hemoglobin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum hepcidin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flow mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: endothelium independent vascular responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of viral clearance at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: life years saved
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of PDPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: exercise intentions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: exercise motivation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Conjunctival injection score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite equilibrium scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brake reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS ratings of 'dizzy', 'high', and 'drug effect'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Use of CAM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retinal arteriolar caliber
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma biomarkers of microvascular endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiometabolic risk markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma PL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decrease in anxiety after the procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: immunologic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: clinical status and outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: linear analogue pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient‐controlled morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative pulmonary function (peak expiratory flow rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response defined as a decrease in the NIH-CPSI total score by at least 25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and unmet needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: IFX trough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal ulcers absence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: S/O, C/O and P/O ratio values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymmetric index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility regained
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: onset time to 95% twitch reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: quality of intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychometric hepatic encephalopathy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ammonia level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: critical flicker frequency scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: discharge to home at 24 hours
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Mean Cmax of BT ophthalmic solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC0-24 h of BT ophthalmic solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic safety profile of BT gel
Endpoint domain: Adverse events/effects
Primary endpoint: Estimated glomerular filtration rate (eGFR) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum creatinine (SCr) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total effective rate of WM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic nonresponse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV‐1 RNA levels <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rewarming rate of core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of heart rate reduction (> 20% reduction from baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal expiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of volunteers with FeO2 >90% at 3 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean FeO2 at 3 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean inward air leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitological efficacy (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous passage of stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean stone expulsion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose required to achieve target blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Colorectal adenoma recurrence risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: target vessel failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum total T(3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum rT(3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroperoxidase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Detection of occult melanoma cells in lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lesion regression rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy to achieve abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of fluid administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported positive reactions to pictures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: psychophysiological reactions to positive pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response/remission criteria (HRSD-score ≤ 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Hb from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Gln concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine L/M ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentration of endotoxin, diamine oxidase and malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death following one or more progression event
Endpoint domain: Mortality/survival
Primary endpoint: Declines in % predicted FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Declines in 6MWD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in free serum α-synuclein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: complete clearance of all warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean changes in wart counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma triacylglycerol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: absolute wingate anaerobic power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative wingate anaerobic power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute wingate anaerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative wingate anaerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 second-repeated jump power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal eosinophils decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bronchodilator use reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 50% MADRS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDD remission (MADRS ≤ 10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total costs for diagnostic imaging
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of TPUs healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of TPUs retained healed at 8-week follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver enzyme levels elevation
Endpoint domain: Adverse events/effects